40 0

COVID drug remdesivir comes at a cost COVID drug remdesivir comes at a cost. Gilead Sciences on Monday applied for approval from the U.S. Food and Drug Administration for its COVID-19 treatment, remdesivir. The biotech company also said the antiviral drug will go by the brand name of Veklury in the U.S. "Today's filing is an important milestone as we continue to partner with the U.S. government and health care authorities around the globe to address the treatment needs of patients with COVID-19," said Merdad Parsey, Gilead's chief medical officer, in a statement. Remdesivir is available in the U.S. on an emergency basis for hospitalized patients with severe cases of COVID-19, but FDA appro... Full story

10 August